A federal judge hearing the bellwether lawsuit for "low-T" drug marketing decided the plaintiff’s case was suffering from a lack of support for some of its claims.
Sanofi's vaccines unit has settled a class-action suit that claimed the company leveraged its heavyweight status in the field to knock back a rival meningococcal jab from Novartis.
Since dodging a hostile buyout attempt from generics maker Mylan, Perrigo hasn’t been doing so hot. And some of the company’s shareholders aren’t pleased.